课题基金 / 基金详情

Validation of the Nlrp1-Casp1-Casp6 pathway as an early therapeutic target of age-dependent cognitive impairment and Alzheimer Disease.

Validation of the Nlrp1-Casp1-Casp6 pathway as an early therapeutic target of age-dependent cognitive impairment and Alzheimer Disease.
验证 Nlrp1-Casp1-Casp6 通路作为年龄依赖性认知障碍和阿尔茨海默病的早期治疗靶点。
批准号:
356925
负责人:
Leblanc Andra C
金额:
$67.43万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-10-01 至 2021-10-01

项目摘要

项目成果

Leblanc Andra C的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The goal of our research is to identify early degenerative events in aged human brains that can be prevented or treated to stop age-dependent memory loss and the ensuing dementia that occurs in Alzheimer Disease. We have focused on an enzymatic protein na
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of caspases in human neuronal cell death and in Alzheimer's disease.
Detection of Tau cleaved by Caspase-6 in the cerebrospinal fluid of individuals with age-related cognitive impairment and Alzheimer disease.
Regulation of Prion Protein Expression, Trafficking and Function.
海外基金